Research Article
Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study
Table 3
Relationship between baseline characteristics and ΔHbA1c in the VLDM and HDM groups by multivariate linear regression analysis (FAS LOCF).
| | VLDM | HDM | | (95% CI) | value | (95% CI) | value |
| | Week 12 | | | | | | Log (baseline TG) | 0.1083 (0.0537, 0.1629) | <0.001 | 0.0800 (-0.0821, 0.2422) | 0.333 | | Plasma creatinine | -0.0035 (-0.0053, -0.0017) | <0.001 | -0.0052 (-0.0104, -0.0000) | 0.052 | | Duration of DM | 0.0231 (0.0163, 0.0298) | <0.001 | 0.0083 (-0.0112, 0.0279) | 0.403 | | Baseline HbA1c | -0.4127 (-0.4455, -0.3799) | <0.001 | -0.2582 (-0.3620, -0.1544) | <0.001 | | Week 24 | | | | | | Log (baseline TG) | 0.0551 (-0.0071, 0.1173) | 0.082 | 0.0761 (-0.0691, 0.2212) | 0.304 | | Plasma creatinine | -0.0036 (-0.0057, -0.0016) | <0.001 | -0.0014 (-0.0061, 0.0032) | 0.541 | | Duration of DM | 0.0234 (0.0157, 0.0311) | <0.001 | 0.0314 (0.0139, 0.0490) | <0.001 | | Baseline HbA1c | -0.4290 (-0.4663, -0.3917) | <0.001 | -0.3325 (-0.4248, -0.2402) | <0.001 |
|
|
TG: triglyceride; FAS: full analysis set; LOCF: last observation carried forward; VLDM: vildagliptin (50 mg bid) plus metformin (500 mg bid); HDM: metformin uptitration (1000 mg bid); 95% CI: 95% confidence interval; HbA1c: glycated hemoglobin; TC: total cholesterol.
|
